MIDI Host microbe dialogue through metabolic interactions
- Coordinator
- The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
- Runs
- 1 November 2026 to 31 October 2031
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101266308
What the project is doing
In the project's own words, from its summary on CORDIS.
The intestinal microbiome is a complex community of organisms that exists in symbiosis with its host. Microbiota perform essential digestive, metabolic, and immunomodulatory functions in health, and disturbance of the microbiota can contribute to disease. Microbial metabolites are a key ingredient in healthy host-microbe dialogue, bolstering barrier immunity and immune regulatory pathways. Our recent work on microbiota-derived small molecule metabolites ADP-heptose and the short chain fatty acid, butyrate, has identified new immune regulatory and microbicidal functions that could be targeted in inflammatory bowel disease.
However, harnessing metabolites as disease therapeutics has been challenging because of their diverse cellular targets and the complex bacterial community ecology governing their production and function. Using our recent technological advances we propose a multi-disciplinary approach spanning the frontiers of immunology, cell biology, gnotobiology, microbial ecology and computational biology, to deconvolute host microbiota interactions over space and time.
Using ADP-heptose and butyrate as exemplars, we will use metabolite-centric designer microbiome communities together with integrated spatial, omics-scale data in tissue sections, to chart the passage of microbiota-derived metabolites into tissue niches to reveal their cellular targets and influence on transcriptomic and proteomic networks relevant to immune regulatory and microbicidal function. In addition to our in vitro-defined cellular pathways, this will identify novel interkingdom targets and opportunities to treat disease niches, leaving other metabolic pathways and cellular interactions unaffected.
Results of these studies will be used to design new vaccine enhancing strategies and more specific therapeutic approaches in IBD patients.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI